NCT05994365招募中不适用
A Real-world Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 380
- 试验地点
- 3
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize the treatment experience in a broad population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients voluntarily participate in this study, sign the informed consent form and had good compliance;
- •Aged 18 ~ 70 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0~1; more than 6 months of expected survival ;
- •Histopathologically confirmed locally advanced or metastatic differentiated thyroid cancer, radiographically documented disease progression within 18 months of absence of radioactive iodine (RAI) therapy;
- •Meet any of the following:
- •Lesions were not iodine-avid: no RAI uptake was confirmed after RAI scan in the presence of a low-iodine diet, adequate thyroid stimulating hormone (TSH) elevation (≥ 30 mIU/L). The definition of no iodine uptake:
- •no iodine uptake initially;
- •exist of iodine uptake initially while lost subsequently;
- •partially uptake;
- •progression disease despite iodine uptake.
- •The cumulative dose of RAI was ≥ 600 mCi or 22 GBq, with an interval of at least 3 months.
- •Radiographically documented disease progression within 18 months of RAI therapy despite the presence of iodine-131 affinity at the time of RAI therapy;
- •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.
- •Major organ functions meet the following criteria within 7 days prior to treatment:
- •Blood routine test criteria (14 days without blood transfusion):
- •Hemoglobin (HB) ≥ 85 g/L;
- •Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;
- •Platelet (PLT) ≥ 80 × 10^9/L
- •Biochemical tests need to meet the following criteria:
- •Total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN);
- •Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2 .5×ULN, ALT and AS if liver metastases T ≤ 5 ×ULN;
- •Serum creatinine (Cr) ≤ 1 .5 ×ULN or creatinine clearance (CCr) ≥ 60 Ml/min;
- •Females of childbearing potential should agree to use contraceptive measures (such as intrauterine device, contraceptives or condoms) during the study and within 6 months after the end of the study; have a negative serum or urine pregnancy test within 7 days before study enrollment and must be non-lactating patients; and males should agree to use contraceptive measures during the study and within 6 months after the end of the study period.
排除标准
- •Comorbidities and medical history:
- •A history of or concurrent with other malignancies within the past 3 years. Patients were eligible if they had disease-free survival (DFS) for 5 consecutive years in other malignancies treated by single surgery; Cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
- •Major surgical treatment, open biopsy, or significant traumatic injury within 28 days before the start of study treatment;
- •Subjects with any severe and/or uncontrolled illness, including:
- •Patients with ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (including Corrected QT Interval (QTc)≥450ms(male), QTc≥ 470ms(female)) and ≥ grade 2 congestive heart failure (NYHA classification);
- •Severe active or uncontrolled infection (≥ grade 2 infection according to Common Terminology Criteria for Adverse Events (CTCAE) );
- •Renal failure requiring hemodialysis or peritoneal dialysis;
- •Patients with concomitant diseases that seriously endanger the safety of patients or affect the completion of the study, or patients who are considered to be unsuitable for enrollment for other reasons according to the judgment of the investigators.
- •patients with previous treatment with anlotinib hydrochloride capsules or similar vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) small molecule drugs, such as vandetanib, Cabozantinib, lenvatinib, sunitinib, or sorafenib, etc.;
研究组 & 干预措施
Anlotinib group
Anlotinib hydrochloride capsules: 12 mg once daily for 2 weeks, followed by a discontinuation of 1 week (21 days as a cycle)
干预措施: Anlotinib Hydrochloride Capsule (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: Baseline up to 3 years.
The proportion of subjects who achieves a best overall response of complete response (CR) or partial response (PR).
Progression-free Survival (PFS)
时间窗: Baseline up to 3 years.
From the first dose to the date of objective disease progression or death, whichever occurs first.
次要结局
- Duration of Response (DOR)(Baseline up to 3 years.)
- Overall Survival (OS)(Baseline up to 3 years.)
- Adverse event rate(Baseline up to 3 years.)
- Disease-control Rate (DCR)(Baseline up to 3 years.)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
4 期
Study of Anlotinib in Patients With Advanced Medullary Thyroid CarcinomaMedullary Thyroid CancerNCT05830500Chia Tai Tianqing Pharmaceutical Group Co., Ltd.360
Unknown
不适用
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Cancer of LiverNCT03766776The First Affiliated Hospital with Nanjing Medical University40
已完成
2 期
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung CancerLung CancerNCT04671303Cancer Institute and Hospital, Chinese Academy of Medical Sciences36
Unknown
不适用
Anlotinib Therapy in Patients With Advanced Lung Cancer.Lung NeoplasmsNCT03940404First People's Hospital of Hangzhou1,000
Unknown
2 期
Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Advanced Hepatocellular CarcinomaNCT04052152The First Affiliated Hospital with Nanjing Medical University20